The Daily Biotech Pulse: Amarin's Vascepa Appeal Hearing, Avid Bioservices' Strong Q1, A Life Sciences Blank Check IPO
Scaling The Peaks
Down In The Dumps
Stocks In Focus Mesoblast Gets Ethics Approval For Using Stem Cell Therapy In COVID-19 Patients In Australia
MESO) said it has received ethics approval to include Australian hospitals in the Phase 3 randomized controlled trial of remestemcel-L in ventilator-dependent COVID-19 patients with acute respiratory distress syndrome.
The company said an independent Data Safety Monitoring Board will complete an interim analysis this month in the trial’s first 90 patients randomized in the US after they have completed 30 days of follow up.
The stock was up 2.16% to $19.36 in pre-market trading.
Castle Biosciences Announces Executive Promotions and Appointment of Medical Director
CSTL) announced the promotion of Toby Juvenal to the role of chief commercial officer. Juvenal has been with the company since Oct. 2008 and was most recently serving as SVP of sales. The company also announced the promotion of Kirsten Oelschlager as chief operations officer and Bob Cook as SVP, R&D.
Castle Biosciences also said Matthew Goldberg has joined the company as Medical Director in August.
Vir Biotech Appoints Former Arizona Governor Napolitano To Its Board
VIR) announced the appointment of former Arizona Governor and former U.S. Secretary of Homeland Security Janet Napolitano to its board of directors, replacing Kristina Burow, who has resigned after four years as a founding director.
Earnings
CDMO) reported fiscal year 2021 first-quarter revenues of $25.4 million, up 66% year-over-year. The increase was attributed primarily to the number and scale of in-process and/or completed manufacturing runs. The company reversed from a loss of 8 cents per share to a profit of 6 cents per share. Analysts had estimated a loss of 7 cents per share.
The company confirmed its fiscal year guidance of $76 million to $81 million, surrounding the consensus estimate of $78.96 million.
The stock jumped 5.05% to $8.95 in after-hours trading.
View more earnings on IBB” data-reactid=”70″>View more earnings on IBB
ITOS) said its second-quarter loss narrowed from $36.49 cents per share to $29.49 cents per share. The company had cash of $136.9 million as of June 30, 2020.
On The Radar
AMRN) Vascepa patent is scheduled to be held. The hearing is to take place telephonically.
adverse ruling in its patent challenge case against generic drug makers Dr.Reddy’s Laboratories Ltd (NYSE: RDY) and Hikma” data-reactid=”74″>In late March, Amarin was handed down an adverse ruling in its patent challenge case against generic drug makers Dr.Reddy’s Laboratories Ltd (NYSE: RDY) and Hikma
“A reversal of the patent invalidation ruling, if it occurs, would likely secure exclusivity for branded Vascepa in the US for a significant period of time (until late in the decade, we think), and is an outcome which we believe is currently not priced-in to share,” Aegis Capital’s Nathan Weinstein said.
IPOs
Each unit consists of one share of Class A common stock and one-third of one redeemable warrant, with each whole warrant exercisable to purchase one share of Class A common stock at a price of $11.50 per share. The company expects the offering to be consummated on Sept. 4.
The company, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, is led by CEO Eli Casdin and Chairman Keith Meister. It said it intends to focus its search for business combination targets in three separate areas of the life sciences industry that are often fragmented – life sciences tools, synthetic biology and diagnostics.
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates ” data-reactid=”80″>Related Link: Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
View Article Origin Here
